Skip Navigation

Center for Patient Derived Models (CPDM)

  • Keith L. Ligon, MD, PhD, in his lab

    Keith L. Ligon, MD, PhD, is director of the Center for Patient Derived Models (CPDM). He is an associate professor of Pathology at Harvard Medical School with joint appointments at Dana-Farber, the Broad Institute of Harvard and MIT, and Brigham and Women’s Hospital (BWH). He is chief of Neuropathology at Brigham and Women’s Hospital. His research and clinical activities have improved the scientific understanding of brain tumors.

  • Advances in our ability to make cancer models from individual patients have created a great opportunity and a new need to incorporate individual patient model generation into clinical trials of experimental therapies. We can now use these models to test therapeutics almost in real time — to identify what therapy the patient may or may not be likely to respond to and therefore, have real potential to change cancer care.

    The Center for Patient Derived Models (CPDM) facilitates model availability and quality for Dana-Farber investigators and the wider cancer community. CPDM supports researchers by generation, characterization, storage, and distribution of models of various types, including cell lines, PDX, and fresh cell preparations.

    Available Patient Derived Cell Line (PDCL) or Patient Derived Xenograft (PDX) Models

    CPDM has one of the largest collections of hematologic cancer PDX models of diverse subtypes, as well as various solid tumor PDX models with clinical and genomic annotations.

  • Collection of Hematologic Cancer PDX Models

    Collection of Hematologic Cancer PDX Models


  • Collection of Solid Tumor PDX Models Based on Anatomical Sites

    Collection of Solid Tumor PDX Models Based on Anatomical Sites

  • Please visit the Public Repository of Xenografts (PRoXe) to view a collection of PDX models available for purchase.

    CPDM also has a large collection of primary and metastatic brain tumor models (a collection of 200 PDCLs and 90 PDXs) that are not listed on the PRoXe website. The primary brain tumor models cover various diagnoses (astrocytoma, meningioma, oligodendroglioma, and others) and include several rare IDH1 R132H models, as well as rare models of oligodendroglioma, gliosarcoma, pineoblastoma, and primitive neuroectodermal tumor. The metastatic brain tumor models have diverse origins of primary cancers (lung, skin, breast, colon, esophagus, testis, and others), from the most common breast carcinoma and lung adenocarcinoma to the rare neuroendrocrine carcinoma, prostate adenocarcinoma, yolk sac tumor, and small cell lung carcinoma.

  • Collection of Metastatic Brain Tumor PDX/PDCL Models

    Collection of Metastatic Brain Tumor PDX/PDCL Models

  • Of the brain patient derived cell line collection, we have a huge collection of 3D tumor spheroid models (>140 unique models), as well as 2D adherent models (>60 unique models). A small collection of these also have matching PDCL and PDX models derived from the same patients.

  • 3D and 2D cell line cultures

  • Many of the models have been sequenced, and they come with rich clinical annotations, including data on whether tumors allocated for model creation are previously exposed to immunotherapy, targeted therapy, chemotherapy, or radiation therapy.

    Please contact us for more information on our tumor model collection. (See "Contact Us" below.)

    Our Team

  • Center for Patient Derived Models (CPDM) team members

  • Keith Ligon, MD, PhD

    Kin-Hoe Chow, PhD
    Associate Director

    Smitha Yerrum
    Lab Manager

    Yu Zeng
    Post-Doctoral Fellow

    Aniket Shetty
    Bioinformatics Analyst

    Claire Sinai
    Clinical Research Coordinator

    Shawna Bilton
    Clinical Research Coordinator

    Tony Tran
    Clinical Research Coordinator

    Pei-Lun Kao
    Research Technician

    Aliya Jaber
    Research Technician

    Abigail Ossip
    Administrative Assistant

    Dylan Freitas
    Lab Assistant

    Nima Faraji
    Lab Assistant

    Contact Us

    To request services, view a list of services, or generate a quote, visit our iLabs page, or contact us at or 617-632-3641.

  • Our Center's Goals

    • Develop and use novel modeling and testing methods for patient derived models.
    • Increase the number of characterized patient derived models available in all adult and pediatric cancers.
    • Create a centralized and specialized infrastructure and resource to enable better access to patient derived cancer modeling capabilities across Dana-Farber, Brigham and Women's Hospital, and Boston Children’s Hospital.
    • Accelerate the use of patient derived cancer models as functional diagnostic assays for sensitivity testing in clinical trials and validated clinical indications.
    • Develop relationships with industry to access and assess new technologies to develop, characterize, and test patient derived cancer models (and make these technologies available to Dana-Farber investigators).